Cardiac Enzymes in Myocardial Infarction (MI)

Introduction

Myocardial infarction (MI), commonly known as a heart attack, occurs when blood flow to the heart muscle is blocked, leading to damage or death of heart tissue. One of the key diagnostic tools for MI is the measurement of cardiac enzymes, which are proteins released into the bloodstream when the heart muscle is injured.

Key Cardiac Enzymes in MI

1. Troponins (Troponin I and Troponin T)

  • Most specific and sensitive markers for myocardial injury.
  • Levels rise 2-4 hours after MI, peak at 12–24 hours, and remain elevated for up to 7–14 days.
  • Even a small increase in troponin levels can indicate heart damage, making it the primary biomarker for detecting MI.

2. Creatine Kinase-MB (CK-MB)

  • Less specific than troponins but useful for detecting reinfarction.
  • Levels start to rise within 4–6 hours, peak at 12–24 hours, and return to normal within 2–3 days.

3. Myoglobin

  • One of the earliest markers to rise, appearing within 1–2 hours after MI onset.
  • Not specific to cardiac muscle (also found in skeletal muscle), so it is less useful in MI diagnosis.

Clinical Use of Cardiac Enzyme Testing

  • Early detection: Serial measurements (at admission, 3–6 hours later, and beyond) help track enzyme trends.
  • Diagnosis Confirmation: Elevated troponin levels in the right clinical context confirm MI.
  • Prognostic Value: Higher levels of troponins correlate with more severe injury and worse outcomes.
  • Guiding Treatment Decisions: Persistent enzyme elevations may indicate ongoing damage and require urgent intervention.

Conclusion

Cardiac enzyme testing, particularly troponins, plays a crucial role in diagnosing and managing myocardial infarction. While other enzymes like CK-MB and myoglobin have supporting roles, troponins remain the gold standard due to their high sensitivity and specificity.

Source recommendations

1. American Heart Association Guidelines for the Management of ST-Elevation Myocardial Infarction

  1. https://professional.heart.org/en/science-news/2021-acc-aha-scai-guideline-for-coronary-artery-revascularization
  2. https://www.ahajournals.org/doi/10.1161/cir.0b013e3182742cf6
  3. https://www.sciencedirect.com/science/article/pii/S073510972106157X
  4. https://www.ahajournals.org/doi/10.1161/01.cir.0000134791.68010.fa
  5. https://pubmed.ncbi.nlm.nih.gov/23256914/

2. European Society of Cardiology Guidelines for the Management of Acute Coronary Syndromes

  1. https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Acute-Coronary-Syndromes-ACS-Guidelines
  2. https://academic.oup.com/eurheartj/article/44/38/3720/7243210
  3. https://pubmed.ncbi.nlm.nih.gov/37622654/
  4. https://academic.oup.com/eurheartj/article/42/14/1289/5898842
  5. https://pubmed.ncbi.nlm.nih.gov/26320110/

Our advantages:

patient2376100
Best practices from USA, EU and Japan
Our answers to your questions are based on the clinical recommendations of countries with the most developed healthcare systems in the field of cardiology in the USA, the EU and Japan.
prescription18648039
Always up-to-date information
On a daily basis, we monitor for you all new scientific research publications in leading scientific journals on medical issues of interest to you.
We monitor all innovations and changes in the field of cardiac disease treatment on a daily basis.
fvfflf7q
Get second opinion
Here you can learn everything that even your doctor may not know about cardiology (if he does not speak English and he does not read 117 leading medical journals on cardiology every month).
1xr4duup
The most comprehensive and up-to-date collection of free cardiology materials
Our website contains the most comprehensive and up-to-date collection of free cardiology materials in your country.
Every 3-5 years, half of the scientific approaches to treatment in the field of cardiology are reviewed as a result of specialized scientific discoveries. With us, you don't have to wait these years to learn about the best ways to treat you and your loved ones.
arrow
Please register in order to receive information regarding possible complications and new approaches to treatment of cardiovascular diseases via email in our Newsletters.
arrow